Skip to main content
OpenTrials
Completed

NCT Number: NCT02373254

NSAIDS Versus Opioids in Acute SER II Ankle Fractures

This study is being conducted to evaluate whether NSAIDS are more or less effective in bone healing than opioids in acute fracture pain. Participants will be randomized to one of three groups for first line treatment of pain related to the fracture.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of California Davis

Sacramento, California, 95817, United States

About this study

Pain management in acute fractures is challenging and influenced by several factors contributing to pain perception. These factors include but are not limited to tissue damage by the local impact, mechanical stress at the fracture ends, and central perception of the noxious stimulus. Tissue damage and mechanical stress leads to inflammation and further to local swelling. Swelling itself is significant contributor in pain development.

Ideal pain management would attack pain development at most sites possible. The current clinical practice in the US applies a derivate of an opioid analgesic combined with acetaminophen, thereby influencing pain development at central perception by the opioid analgesic and acetaminophen and a peripheral analgesic effect of acetaminophen. The exact mechanism of the peripheral effect is not known.

This clinical practice disregards the positive effect of medications influencing the peripheral inflammatory response, namely nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs affect pain development by blocking the synthesis of arachidonic acid metabolites, inhibiting peripheral inflammatory response and central pain perception. The major reason for not applying NSAIDs in the treatment of acute fracture pain is an experimental animal study showing decreased bone healing in relation to NSAID usage.

However, clinical data thus far is inconclusive, whether bone healing is affected in humans and whether NSAIDs should be avoided in the setting of bone fractures.

This proposed study will give an answer whether the usage of NSAIDs in acute fractures has a negative effect on bone healing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 to < 60
  • Isolated ankle fracture type SER II
  • Ability to speak and understand English
  • BMI< 35

Exclusion criteria

  • ASA>3
  • Previous or acute gastric bleeding
  • Renal insufficiency (Creatinine: >1.27mg/dl)
  • Liver insufficiency (Child-Pugh-Wert: 10-15)
  • Malignant tumor
  • Rheumatoid arthritis
  • Heart failure (NYHA III-IV)
  • High frequency absolute arrhythmia
  • Patients with known psychiatric illness
  • Coagulopathy
  • Asthma
  • Function limiting disease of the lower extremity, besides what is mentioned in the inclusion criteria
  • Adults unable to consent
  • Pregnant women
  • Prisoners
  • Workers Comp patient
  • Early fracture displacement (within first 2 weeks) indicating need for surgery
  • Polytrauma
  • Concurrent participation in another clinical trial

Treatment and study plan

Ibuprofen

Drug

Ibuprofen 400 mg and 800 mg

Other names: Motrin

Acetaminophen/hydrocodone

Drug

Norco 5/325 mg and 10/325 mg

Other names: Norco

Primary outcomes

  1. fracture healing as measured by radiographic evaluation

    Time frame: 12 weeks

    fracture healing at 12 weeks followup

Secondary outcomes

  1. pain level improvement as measured by VAS score

    Time frame: 1 week, 2 weeks, 6 weeks, 9 weeks and 12 weeks

    VAS score

  2. functional improvement as measured by AAOS score

    Time frame: 1 weeks, 2 weeks 6 weeks, 9 weeks and 12 weeks

    AAOS scale

Sponsors and collaborators

Lead sponsor

University of California, Davis

Other

Registry information

Official study title

Pain Management With NSAIDS in Acute Ankle Fractures Type Supination, External Rotation (SER) II: A Prospective Randomized, Single Blinded Controlled Study

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Feb 26, 2015
Registry last updated
Jul 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.